Throughout his career, Dr. Bearss has contributed to multiple professional journals, authoring hundreds of articles.
ALPINE, UT, July 19, 2024 /24-7PressRelease/ -- David J. Bearss, PhD has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
A seasoned business owner with decades of experience in education, medicine, pharmaceuticals, and more, Dr. Bearss excels as the co-founder, chairman, and chief executive officer of Halia Therapeutics and senior managing director of the Therapeutics Accelerator at the University of Utah. Similarly, he is a partner with UVB Capital Management LLC and co-founder and chairman of Biolexis Therapeutics. In addition to his professional endeavors, Dr. Bearss leverages his considerable expertise on the Canary Speech and BIO Utah board of directors and as a scientific advisor for Systems Oncology.
Over the years, Dr. Bearss has honed his leadership expertise in various positions with Xenthera, Xenter, Inc., Sumitomo Pharma Co., which he founded under the name Tolero Pharmaceuticals, Tetragene LLC, and The Center for Investigational Therapeutics. A testament to his dedication to mentorship, he has taught students at the University of Utah's Huntsman Cancer Institute and Department of Oncological Sciences, Brigham Young University, and the University of Arizona. Likewise, Dr. Bearss has contributed his vast knowledge to executive and research positions with such notable companies as Salarius Pharmaceuticals, Inc. SuperGen Inc., the Arizona Cancer Center, and Wasatch Clinical Research, LLC.
Throughout his career, Dr. Bearss has contributed to multiple professional journals, authoring hundreds of articles, including "A Prospective Biomarker Analysis of Alvocidib Followed by Cytarabine and Mitoxantrone in MCL-1-Dependent Relapsed/Refractory Acute Myeloid Leukemia" and "Single-cel Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer." Alongside other industry scholars, Dr. Bearss has also co-written such work as "A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis" and "Are Accurins the Cure for Aurora Kinase Inhibitors?"
Dr. Bearss, an expert in his field, earned a Bachelor of Science in human biology from Brigham Young University in 1994. Subsequently, he expanded his professional knowledge by completing a PhD in cell and structural biology and a postdoctoral degree in oncology and cancer biology at the University of Texas Health San Antonio. Driven to remain abreast of changes in the field, Dr. Bearss aligns himself with several industry organizations, including the American Society of Clinical Oncology and the American Society of Hematology.
In light of his professional achievements, Dr. Bearss was named a Top 100 Venture Entrepreneur through Signal Peak Ventures and earned a CEO Award from Finance Monthly. Since 2012, he has received two Utah Innovation Awards from the Utah Technology Council and a Medal of Science from the Utah Governor's Office. While his career has been filled with highlights, he takes the most pride in witnessing the impact of his work. Though hard work and dedication have brought him far in his career, he credits his success to his wife's support and the help of his network. Dr. Bearss intends to take his companies to the next level in the coming years.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
# # #